We are live on ! Find out more
TLX

Telix Pharmaceuticals
TLX

21 hedge funds and large institutions have $7.29M invested in Telix Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 1

812% more capital invested

Capital invested by funds: $799K → $7.29M (+$6.49M)

250% more funds holding

Funds holding: 6 → 21 (+15)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.12% more ownership

Funds ownership: 0.01% → 0.13% (+0.12%)

Holders
21
Holders Change
+15
Holders Change %
+250%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Pier Capital
Connecticut
+$3.17M
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$1.01M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$707K
4
Citadel Advisors
Citadel Advisors
Florida
+$694K
5
Jane Street
Jane Street
New York
+$589K

Top Sellers

Rank Fund Capital Flow
1
AA
ABC Arbitrage
France
-$451K
2
Morgan Stanley
Morgan Stanley
New York
-$20.7K
3
EWA
EverSource Wealth Advisors
Alabama
-$1.18K
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
1
Pier Capital
Connecticut
$3.04M +$3.17M +188,992 New
Russell Investments Group
2
Russell Investments Group
United Kingdom
$975K +$1.01M +60,301 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$681K +$707K +42,091 New
Citadel Advisors
4
Citadel Advisors
Florida
$668K +$694K +41,328 New
Jane Street
5
Jane Street
New York
$564K +$589K +35,103 New
PAG
6
Private Advisor Group
New Jersey
$404K +$252K +15,027 +148%
Vanguard Personalized Indexing Management
7
Vanguard Personalized Indexing Management
California
$297K +$310K +18,475 New
William Blair & Company
8
William Blair & Company
Illinois
$217K +$227K +13,500 New
IWM
9
IHT Wealth Management
Illinois
$213K +$222K +13,240 New
UBS Group
10
UBS Group
Switzerland
$98.4K +$41.5K +2,470 +68%
Morgan Stanley
11
Morgan Stanley
New York
$70.7K -$20.7K -1,232 -22%
Raymond James Financial
12
Raymond James Financial
Florida
$19.3K +$20.1K +1,200 New
RhumbLine Advisers
13
RhumbLine Advisers
Massachusetts
$19.2K +$688 +41 +4%
AAP
14
Arax Advisory Partners
Colorado
$16.6K +$17.3K +1,030 New
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$2K +$2.37K +141 New
EWA
16
EverSource Wealth Advisors
Alabama
$1.08K -$1.18K -70 -51%
Osaic Holdings
17
Osaic Holdings
Arizona
$723 +$756 +45 New
JWA
18
JFS Wealth Advisors
Pennsylvania
$434 +$453 +27 New
PS
19
Principal Securities
Iowa
$337 +$353 +21 New
AssetMark Inc
20
AssetMark Inc
California
$289 +$302 +18 New
TWD
21
True Wealth Design
Ohio
$161 +$168 +10 New
AA
22
ABC Arbitrage
France
– -$451K -26,939 Closed

TLX Hedge Fund Activity: Q2 2025 in Review

21 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q2 2025, worth a combined $7.29M — up 812% from $799K a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TLX positions and 1 closed out — a net gain of 15 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Pier Capital, opening a new position worth an estimated $3.17M. The largest seller was ABC Arbitrage, exiting entirely with an estimated $451K sold.

  • 21 institutional investors held Telix Pharmaceuticals (TLX) as of Q2 2025, up from 6 in Q1 2025.
  • Funds reported $7.29M of Telix Pharmaceuticals stock for Q2 2025, up 812% quarter-over-quarter.
  • 16 funds opened new Telix Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of +15 holders.
  • The largest Telix Pharmaceuticals buyer in Q2 2025 was Pier Capital, an estimated $3.17M added.
  • The largest Telix Pharmaceuticals seller in Q2 2025 was ABC Arbitrage, an estimated $451K sold.

Based on aggregated 13F filings for Q2 2025.